Hakan Goker

TRIMTECH has a growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTAC® and TRIMGLUE®. The pipeline is focused around the development of treatments for severe neurodegenerative and inflammatory disorders, including Alzheimer’s and Huntington’s disease.

At ReproNovo, we are redefining whats possible in reproductive medicine and women’s health. We are advancing innovative therapeutic solutions for both male and female infertility, as well as pioneering treatment options for uterine conditions like adenomyosis, delivering meaningful change to patients worldwide. Our international team brings together deep expertise across reproductive medicine, drug development, regulatory strategy, and business development—with a proven track record of bringing multiple therapies to market. ReproNovo is backed by leading investors including Jeito Capital, AXA IM Alts, M Ventures, Ysios Capital, and ALSA Ventures. Headquartered in Lausanne, Switzerland, our primary development team is located in Copenhagen, Denmark, with an additional development site in Barcelona, Spain. Imprint ReproNovo S.A. Rue de Langallerie 11 1003 Lausanne, Switzerland E-Mail: info@repronovo.com Chief Executive Officer & Co-Founder: Jean Duvall Chief Scientific & Medical Officer & Co-Founder: Joan-Carles Arce Chief Financial Officer & Co-Founder: BingMei Hao

Nouscom is a clinical-stage biotech company redefining cancer immunotherapy through its proprietary viral vector platform. Headquartered in Basel, Switzerland, Nouscom develops both off-the-shelf and personalized neoantigen immunotherapies that activate robust and durable T cell responses in cancer patients. Our lead program, NOUS-209, is advancing toward registrational for cancer interception in Lynch Syndrome carriers, a transformative opportunity for these patients. The program has received positive regulatory feedback with a global registrational trial expected to launch in H1 2026. Nouscom’s second clinical program, NOUS-PEV, is a personalized immunotherapy for advanced solid tumors. It has demonstrated clinical responses in metastatic melanoma patients and is supported by a fully automated GMP manufacturing process that enables scalable delivery within 8 weeks. Nouscom is supported by leading life sciences investors including 5AM Ventures, Andera Partners, M Ventures, Bpifrance, EQT Life Sciences, Indacos, Panakes, Revelation, Versant Ventures and XGen Ventures. Our platform is clinically validated in over 170 patients and offers unmatched immunogenicity, scalability, and safety — positioning Nouscom as a frontrunner in the next generation of cancer immunotherapy. 🔗 Learn more at http://www.nouscom.com

Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. Its proprietary Esterase Motif Technology (ESM) platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner, activating the body's natural immune system to fight cancer. The platform has the ability to provide next-generation immunotherapies for a number of different cancers. Founded by the CRT Pioneer Fund (CPF), the Company recently raised £9 million in a Series A financing round, led by CPF and two new specialist investors, Novo A/S and Aglaia Biomedical Ventures BV. Macrophage Pharma’s strategy is to complete the preclinical development of its lead development candidate, a p38 MAP kinase inhibitor, and advance two additional discovery candidates into pre-clinical development. The company's management team, led by Dr Søren Bregenholt, Chief Executive Officer, has a track record of success in the pharma industry ranging from early discovery to commercialisation. The Scientific Advisory Board is comprised of world-leading immunologists and cancer researchers who will help shape the future development of the company’s unique approach in immuno-oncology. For more information, please visit the company website: www.macrophagepharma.com

Artios is a leading independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Artios began clinical trials in February 2021 of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumours. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery and PARP inhibitors; key staff at Artios developed the drug olaparib (Lynparza ™). Artios is building a pipeline of next-generation DDR programmes, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. We are a rapidly expanding company that is often looking for new talent. If you have the qualities to be part of our team, please submit your application via our website. We are also very mindful of scams that involve recruitment. At this time please note we are currently not working with any third parties in India for recruitment.

STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets. STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first in class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases. The pipeline is exemplified by STORM’s METTL3 inhibitor (STC-15) for which an IND has been filed with the FDA to support initiation of a Phase I clinical trial in cancer patients in 2022. STC-15 represents the first RNA modifying enzyme inhibitor to enter clinical evaluation in humans. Additional candidates are planned for advancement into IND-track activities in 2023. STORM has built an experienced R&D team who occupy modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK. The company’s proprietary in house research is complemented by outsourcing of some discovery activities to high quality CRO partners (e.g., Evotec) enabling STORM to operate a cost efficient and flexible model.

Orphazyme is a global biopharmaceutical company, headquartered in Denmark, with a rapidly growing presence in the United States. We are pioneering a new kind of treatment, applying our specialized expertise to bring innovative therapies to patients with neurodegenerative orphan diseases. With a late-stage drug pipeline, we are relentless in our commitment to advancing treatments and making a profound impact for those touched by these rare, serious diseases. Today we are listed on Nasdaq Copenhagen (TICKER: ORPHA.CO) and Nasdaq U.S. (TICKER: ORPH), and are expanding our global presence with offices in Denmark, Switzerland, and our US headquarters in Chicago. See our community guidelines: bit.ly/3uapRYr

TRIMTECH has a growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTAC® and TRIMGLUE®. The pipeline is focused around the development of treatments for severe neurodegenerative and inflammatory disorders, including Alzheimer’s and Huntington’s disease.

At ReproNovo, we are redefining whats possible in reproductive medicine and women’s health. We are advancing innovative therapeutic solutions for both male and female infertility, as well as pioneering treatment options for uterine conditions like adenomyosis, delivering meaningful change to patients worldwide. Our international team brings together deep expertise across reproductive medicine, drug development, regulatory strategy, and business development—with a proven track record of bringing multiple therapies to market. ReproNovo is backed by leading investors including Jeito Capital, AXA IM Alts, M Ventures, Ysios Capital, and ALSA Ventures. Headquartered in Lausanne, Switzerland, our primary development team is located in Copenhagen, Denmark, with an additional development site in Barcelona, Spain. Imprint ReproNovo S.A. Rue de Langallerie 11 1003 Lausanne, Switzerland E-Mail: info@repronovo.com Chief Executive Officer & Co-Founder: Jean Duvall Chief Scientific & Medical Officer & Co-Founder: Joan-Carles Arce Chief Financial Officer & Co-Founder: BingMei Hao

Nouscom is a clinical-stage biotech company redefining cancer immunotherapy through its proprietary viral vector platform. Headquartered in Basel, Switzerland, Nouscom develops both off-the-shelf and personalized neoantigen immunotherapies that activate robust and durable T cell responses in cancer patients. Our lead program, NOUS-209, is advancing toward registrational for cancer interception in Lynch Syndrome carriers, a transformative opportunity for these patients. The program has received positive regulatory feedback with a global registrational trial expected to launch in H1 2026. Nouscom’s second clinical program, NOUS-PEV, is a personalized immunotherapy for advanced solid tumors. It has demonstrated clinical responses in metastatic melanoma patients and is supported by a fully automated GMP manufacturing process that enables scalable delivery within 8 weeks. Nouscom is supported by leading life sciences investors including 5AM Ventures, Andera Partners, M Ventures, Bpifrance, EQT Life Sciences, Indacos, Panakes, Revelation, Versant Ventures and XGen Ventures. Our platform is clinically validated in over 170 patients and offers unmatched immunogenicity, scalability, and safety — positioning Nouscom as a frontrunner in the next generation of cancer immunotherapy. 🔗 Learn more at http://www.nouscom.com

M Ventures is a strategic, corporate venture capital fund investing in Biotechnology - with verticals in Healthcare and Life Science tools - and Technology - with verticals in Semiconductors and Displays as well as Sustainable Manufacture.